



# Precision Therapies for Amyloid Diseases

Molly Jansky, Mark Provost, Linjing Xie, Shandion Santoso

In Partnership with W Vallen Graham, Manija Kazmi,  
Sharon Blaettler

## THE TEAM

# Experienced Team of Amyloid Pioneers, Drug Developers, and Advisors

### Core Team



**thelium**  
therapeutics



**W Vallen Graham, M.S., Ph.D.**

Co-Founder, CEO

- Founding CSO, Thelium Tx
- Leader in cutting-edge amyloid research



**Manija Kazmi, M.S.**

Co-Founder, Ops & Outreach

- Accomplished scientist bridging amyloid research with operational scale



**Sharon Blaettler, Ph.D.**

Co-Founder, Drug Discovery & Strategy

- Drug developer with 13 years of experience in both Pharma and Biotech

### Student Team



Linjing Xie



Mark Provost



Molly Jansky



Shandion Santoso



Matt Rappaport




Viktor Ström

### Student Mentors

## THE PROBLEM

# Alzheimer's Disease Needs Precision Tools



Current treatments have shown **limited effectiveness** and **lack specificity**

## THE SOLUTION

Chaperone-Like Amyloid Modulating Proteins (CLAMPs) enable both precision diagnostics and targeted therapy.



## COMPETITIVE LANDSCAPE

Current treatments lack specificity, and have harmful side effects.



CLAMPs technology targets specific **toxic** morphotypes, enabling earlier, more precise treatment



Kisunla  
35% cognitive decline improvement




Leqembi  
27% cognitive decline improvement

Kisunla and Leqembi target  $A\beta$  plaques and protofibrils (respectively)

## MARKET POTENTIAL AND TRACTION

### Why Amyloid remains viable target

#### Alzheimer's Market is Growing



#### Recent Major Deals in the Space

December 19, 2024

Bristol Myers Squibb pays BioArctic **\$100 million** upfront with up to **\$1.25 billion** in milestones to license two pyroglutamate-amyloid-beta antibodies

December 11, 2024

Abbvie acquires Aliada Therapeutics for **\$1.4 billion** for its anti-pyroglutamate amyloid beta (3pE-A $\beta$ ) antibody

## VISION AND STRATEGY

# Transforming Alzheimer's Care through Partnerships and Strategic Growth

### Revenue Streams

Year 3: Licensing fees (Diagnostics/Pharma)

Year 4: Upfront payments

Year 5+: Milestone payments and royalties



Early revenue from  
Diagnostic/Pharma  
licensing



Strategic Pharma  
partnerships to scale  
CLAMPs for rapid  
commercialization



Exit Strategies:  
Acquisition by  
Pharma/Biotech  
(estimated ROI 8-15x),  
IPO: within 5-7 years

THANK YOU!